Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network

被引:0
|
作者
Conover, Mitchell M. [1 ,2 ]
Albogami, Yasser [1 ,3 ]
Hardin, Jill [1 ,2 ]
Reich, Christian G. [1 ,4 ]
Ostropolets, Anna [1 ,2 ,5 ]
Ryan, Patrick B. [1 ,2 ,5 ]
Observational Hlth Data Sci and Informatics OHDSI Res Network
机构
[1] Observat Hlth Data Sci & Informat, New York, NY 10032 USA
[2] Johnson & Johnson, Observat Hlth Data Analyt, Titusville, NJ 08560 USA
[3] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh, Saudi Arabia
[4] IQVIA, Real World Solut, Cambridge, MA USA
[5] Columbia Univ, Dept Biomed Informat, New York, NY USA
关键词
chronic lower respiratory disease; common data model; glucagon-like peptide 1 receptor agonists; pharmacoepidemiology; real world data; real world evidence; reliability; replicability; reproducibility; transparency; REPRODUCIBILITY; CALIBRATION; BALANCE;
D O I
10.1002/pds.70087
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
IntroductionThe aim of this study is to use observational methods to evaluate reliability of evidence generated by a study of the effect of glucagon-like peptide 1 receptor agonists (GLP-1RA) on chronic lower respiratory disease (CLRD) outcomes among Type-2 diabetes mellitus (T2DM) patients.Research Design and MethodsWe independently reproduced a study comparing effects of GLP-1RA versus dipeptidyl peptidase-4 inhibitors (DPP4-i) on CLRD outcomes among patients with T2DM and prior CLRD. We reproduced inputs and outputs using the original study data (national administrative claims) and evaluated the robustness of results in comparison to alternate design/analysis decisions. To evaluate generalizability, we applied an analysis protocol and conducted a meta-analysis across a research network that includes a diverse array of populations and data sources. We also produced additional analyses evaluating individual drugs within the GLP-1RA class and CLRD outcomes.ResultsWe confirmed alignment of study inputs and outputs and closely reproduced effect estimates and sensitivity analyses. Adjusted effect estimates were robust to empirical calibration. Network meta-analysis confirmed original findings but indicated weaker effects than originally published. Meta-analysis of drugs within the GLP-1RA class against DPP4-i provided evidence that effects vary within the GLP-1RA class, indicating stronger effects for exenatide and weaker effects of dulaglutide.ConclusionsThis study supports and establishes the reliability of the original study by (1) producing consistent findings in a range of alternate databases and populations, (2) demonstrating effects for multiple drugs within the GLP-1RA class, and (3) independently confirming the reproducibility of the original study and its findings. This reliability evaluation provides the beginnings of a broader framework for using standardized tools and distributed data networks to systematically interrogate the reliability of findings generated using observational data.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes
    Albogami, Yasser
    Cusi, Kenneth
    Daniels, Michael J.
    Wei, Yu-Jung J.
    Winterstein, Almut G.
    DIABETES CARE, 2021, 44 (06) : 1344 - 1352
  • [2] Glucagon-like peptide-1 receptor agonists for treating chronic kidney disease in patients with type 2 diabetes
    Khan, Irfan
    Lanktree, Matthew B.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (40) : E1345 - E1345
  • [3] Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352
    Foer, Dinah
    Cahill, Katherine N.
    DIABETES CARE, 2021, 44 (08) : E165 - E166
  • [4] The effectiveness of glucagon-like Peptide-1 receptor agonists in preventing hospitalizations for chronic lower respiratory disease
    Albogami, Yasser
    Cusi, Kenneth
    Daniels, Michael
    Wei, Yu-Jung Jenny
    Winterstein, Almut
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 224 - 224
  • [5] Relationship between Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Disease in Chronic Respiratory Disease and Diabetes
    Yeh, Jun-Jun
    Li, Chih-Chien
    Tan, Chang-Wen
    Li, Chia-Hsun
    Tsai, Tung-Han
    Kao, Chia-Hung
    BIOMEDICINES, 2024, 12 (03)
  • [6] Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352 RESPONSE
    Albogami, Yasser
    Cusi, Kenneth
    Daniels, Michael J.
    Wei, Yu-Jung J.
    Winterstein, Almut G.
    DIABETES CARE, 2021, 44 (08) : E167 - E167
  • [7] Glucagon-like peptide-1 receptor agonists to treat chronic kidney disease associated with type 2 diabetes
    Khan, Irfan
    Lanktree, Matthew B.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2025, 197 (06) : E165 - E166
  • [8] Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus
    Guyton, Justinne
    Jeon, Michelle
    Brooks, Amie
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (21) : 1739 - 1748
  • [9] Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    Hansen, K. B.
    Knop, F. K.
    Holst, J. J.
    Vilsboll, T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (08) : 1154 - 1160
  • [10] Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease A Review
    Honigberg, Michael C.
    Chang, Lee-Shing
    McGuire, Darren K.
    Plutzky, Jorge
    Aroda, Vanita R.
    Vaduganathan, Muthiah
    JAMA CARDIOLOGY, 2020, 5 (10) : 1182 - 1190